

PHARMACY AND THERAPEUTICS COMMITTEE MEDICAID MEETING MINUTES

May 13, 2025

Attendance:

Microsoft Teams Meeting

Yumna Ahmed, Pharmacy Student Intern; Dr. Paul Aitken, Medical Director; Dr. Rick Buzard, Associate Chief Medical Officer; Connie Chan, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director of Pharmacy; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Hailey Fry, Centennial Pharmacy; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Samantha Jackson, Clinical Pharmacist; Ruth John, Pharmacy Resident; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Brandi Mahler, Supervisor Pharmacy Technicians; Lisa Murray, Staff/Clinical Pharmacist; Kateryna Olchowecky, Clinical Programs Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Sara Sadiq, Staff/Clinical Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Pharmacy Resident; Jessica Tran, Staff/Clinical Pharmacist; Fallan Vaisberg, Formulary Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Jeanine Zubrzycki, Staff/Clinical Pharmacist

Excused:

Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Kevin Caputo, Magellan Health; Dr. Demian Elder, Medical Director; Sanjiv Raj, Associate VP Customer Engagement; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
Minutes Review/Approval	<i>D. Dolores presented the minutes from the March 2025 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>D. Dolores</i>	<i>Resolved</i>


II. Drug Formulary Review/Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
Non-PDL Prior Authorization Criteria Review	<p>The Committee reviewed the Non-PDL Prior Authorization Criteria and approved as presented.</p> <ul style="list-style-type: none"> Crysvita Xdemvy 	The Committee approved as presented.	R. John J. Crawford	Resolved
Quantity Limit Additions	<p>The Committee reviewed the Quantity Limit Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> Journavx 50 mg tablet - 2.5/day, limited to 14-day supply Pyzchiva 130 mg/26 mL vial - 1.86/day Pyzchiva 45 mg/0.5 mL syringe - 0.02/day Pyzchiva 90 mg/mL syringe - 0.04/day Rybelsus 1.5 mg, 4 mg, 9 mg tablet - 1/day Ustekinumab-ttwe 130mg/26mL vial - 1.86/day Ustekinumab-ttwe 45mg/0.5mL syringe - 0.02/day Ustekinumab-ttwe 90 mg/mL syringe - 0.04/day Zepbound 7.5mg/0.5mL and 10 mg/0.5mL vial - 0.072/day (Medicaid); NF (CHIP) 	The Committee approved the Quantity Limit Additions as presented. It will be sent to PARP for approval.	S. Jackson	Resolved
Medicaid 90-Day Supply Removals	<p>The Committee reviewed the Medicaid 90-Day Supply Removals. The Committee approved as presented. Effective June 1, 2025.</p> <ul style="list-style-type: none"> Bydureon Byetta Liraglutide Ozempic Rybelsus Trulicity Victoza Soliqua Xultophy Aimovig Emgality 	The Committee approved as presented. The Medicaid 90-Day Supply Removals will be sent to PARP for approval.	S. Jackson	Resolved
III. Specialty Drug Additions	<p>The Committee reviewed the Specialty Drug Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> Amvuttra 25mg/0.5mL syringe Encelto implant Livmarli 9.5mg/mL, 19mg/mL solution Qfitlia 20mg/0.2mL, 50mg/0.5mL injection Vanraqia 0.75mg tablet 	The Committee approved as presented. The Specialty Drug Additions will be sent to PARP for approval.	S. Jackson	Resolved
IV. New Drug Review	<p>R. John presented the New Drug Review list to the Committee. The following new products were reviewed and will be kept as non-formulary:</p> <ul style="list-style-type: none"> Penpulimab-kcqX Injection 	The Committee approved the New Drug Review as presented and recommended.	R. John	Resolved

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
	<ul style="list-style-type: none"> • <i>Jobevne (bevacizumab-nwgd) Injection</i> • <i>Vanrafia (atrasentan) Tablets</i> • <i>Qfitlia (fitusiran) Injection</i> • <i>Vykat XR (diazoxide choline) Extended-Release Tablets - formerly DCCR</i> • <i>Blujepa (gepotidacin) Tablets</i> • <i>Conexxence (denosumab-bnht) Injection</i> • <i>Bomyntra (denosumab-bnht) Injection</i> • <i>Gozellix (gallium Ga 68 gozetotide) Injection Kit</i> • <i>Arbli (losartan potassium) Oral Suspension</i> • <i>Omlyclo (omalizumab-igec) Injection</i> • <i>Encelto (revakinagene taroretcel-lwey) Intravitreal Implant - formerly NT-501</i> • <i>Stoboclo (denosumab-bmwo) Injection - formerly CT-P41</i> • <i>Osenvelt (denosumab-bmwo) Injection - formerly CT-P41</i> • <i>Miudella (copper) Intrauterine System</i> • <i>Ctexli (chenodiol) Tablets</i> 			

V. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held August 2025.



5/22/2025

Danielle Dolores, Director of Pharmacy Services

Date